Davis Polk advised Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., Credit Suisse Securities (USA) LLC, BNP Paribas Securities Corp. and RBS Securities Inc. as joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $500 million principal amount of its 1.750% notes due 2019, $500 million principal amount of its 3.250% notes due 2023 and $500 million principal amount of its 4.500% notes due 2044.
Headquartered in New York City, Bristol-Myers Squibb Company engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in six foreign countries.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., associates Connor Kuratek and Cherie H. Yang and law clerk David He. The tax team included partner Michael Mollerus and associate Dao Fu. Counsel Betty Moy Huber and associate Kevin J. Klesh provided environmental advice. The intellectual property team included associate Bruce Rose-Innes and law clerks Natalie A. Thomas and Nikita A. Tuckett. Rosemarie Melendez was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
